13 May 2022 - - US-based medical technology company Reflow Medical, Inc has completed patient enrollment in the DEEPER OUS clinical trial (NCT03807531) for the company's Temporary Spur Stent System, a novel device that features a retrievable stent designed for complex infrapopliteal disease, the company said.

106 patients have now been enrolled in the prospective, nonrandomized trial in multiple centers in Europe and New Zealand.

Intended for use in conjunction with a commercially available drug-coated balloon, the Temporary Spur Stent features a self-expanding nitinol scaffold with radially expanding spikes designed to penetrate the diseased vessel wall and enhance drug delivery, without leaving anything behind.

Andrew Holden, MD, director of Interventional Radiology at Auckland City Hospital and Professor of Radiology at the University of Auckland, is also one of the Principal Investigators for the Temporary Spur Stent System trial.

Reflow Medical is in the design and development of innovative and effective technologies for cardiovascular disease.

The Reflow product portfolio includes products used to treat cardiovascular disease in the peripheral vasculature as well as the coronary arteries.